Chemomab Therapeutics (NASDAQ:CMMB) Stock Price Down 3.8% – Here’s Why

Chemomab Therapeutics Ltd. (NASDAQ:CMMB)’s share price fell 3.8% during trading on Wednesday . The stock traded as low as $1.23 and last traded at $1.26. 118,229 shares were traded during mid-day trading, a decline of 39% from the average session volume of 194,593 shares. The stock had previously closed at $1.31.

Chemomab Therapeutics Trading Down 3.8 %

The firm has a market cap of $13.92 million, a PE ratio of -0.79 and a beta of 0.52. The company has a 50-day simple moving average of $1.56 and a 200 day simple moving average of $1.16.

Chemomab Therapeutics (NASDAQ:CMMB) last released its quarterly earnings results on Wednesday, August 21st. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.06). During the same quarter in the prior year, the business posted ($0.72) EPS. On average, equities analysts expect that Chemomab Therapeutics Ltd. will post -1 earnings per share for the current year.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).